Among patients with secondary progressive multiple sclerosis (MS) who received siponimod or placebo during a double-blind trial and entered an open-label extension, those who received siponimod ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

Patricia K. Coyle, MD, FAAN, FANA: Now, where does siponimod fit with all of this? That’s a sphingosine 1-phosphate receptor [S1P] modulator, right? Thomas P. Leist, MD, PhD: It’s an S1P. It’s an oral ...

MINNEAPOLIS - People with the advanced form of multiple sclerosis (MS) called secondary progressive MS who took the drug siponimod for one to two years had improved cognitive processing speed compared ...

On Feb. 8, a new study on the multiple sclerosis drug siponimod conducted by researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center was published in Nature Communications.

Researchers say a multiple sclerosis drug meant to slow physical disability also shows promise in improving mental acuity in people who are living with secondary progressive MS, an advanced form of ...

There are currently 2 widely accepted treatment strategies for MS: escalation and induction therapy. Escalation therapy begins with agents that are associated with less pronounced risk, but also may ...

ZURICH (Reuters) - Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis. The Phase ...